Precision BioSciences/$DTIL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Precision BioSciences
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
- Ticker
- $DTIL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 69
- Headquarters
- Durham, United States
- Website
- precisionbiosciences.com
DTIL Metrics
BasicAdvanced
$349M
-
-$1.59
1.35
-
Price and volume
Market cap
$349M
Beta
1.35
52-week high
$11.29
52-week low
$3.53
Average daily volume
369K
Financial strength
Current ratio
10.469
Quick ratio
9.897
Long term debt to equity
0.503
Total debt to equity
0.535
Interest coverage (TTM)
-28.56%
Profitability
EBITDA (TTM)
-35.037
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-85.58%
Operating margin (TTM)
-80.27%
Revenue per employee (TTM)
$650,000
Management effectiveness
Return on assets (TTM)
-21.13%
Return on equity (TTM)
-115.28%
Valuation
Price to revenue (TTM)
4.93
Price to book
4.93
Price to tangible book (TTM)
5.03
Price to free cash flow (TTM)
-4.234
Free cash flow yield (TTM)
-23.62%
Free cash flow per share (TTM)
-2.161
Growth
Revenue change (TTM)
6,353.01%
Earnings per share change (TTM)
-80.92%
3-year revenue growth (CAGR)
-4.85%
3-year earnings per share growth (CAGR)
-56.65%
What the Analysts think about DTIL
Analyst ratings (Buy, Hold, Sell) for Precision BioSciences stock.
Analyst projections of the future price of Precision BioSciences stock.
Bulls say / Bears say
At the planned 0.4 mg/kg dose, PBGENE-HBV made pgRNA undetectable in all evaluable patients, with liver biopsies also showing cccDNA reductions. Precision is moving the programme into Phase 2, giving it a chance to build on promising early evidence against the root cause of hepatitis B. (SEC)
The first PBGENE-DMD patient had no serious adverse events or events of special interest through week eight, and the safety board supported treating more patients. The approach aims to restore the body’s near full-length dystrophin and is being tested in children whose mutations may cover up to 60% of boys with DMD. (Precision BioSciences)
A partnered ARCUS programme offers another source of clinical validation: iECURE reported fewer hyperammonaemic events and crises in its low-dose cohort of ECUR-506, and completed dosing across the Phase 1/2 cohorts. This provides potential platform value beyond Precision’s two lead programmes. (SEC)
PBGENE-HBV’s encouraging results are still early and biomarker-led: 25 patients had received 59 administrations, and the Phase 2 study is intended to test whether these signals can translate into viral or functional cure. The reported biomarker changes have not yet established a cure in patients. (SEC)
Precision has reported inflammatory responses with repeat lipid-nanoparticle doses, including hypotension and raised liver enzymes. These reactions could make repeat dosing more difficult or constrain the dose patients can tolerate. (Investing.com)
The company has no product sales and reported $20.4 million of operating expenses in the third quarter; it continues to rely on financing while its therapies are in development. Its 10-Q records further share sales through the ATM facility, so funding needs carry dilution risk. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 10 Nov 2026.
DTIL Financial Performance
Revenues and expenses
DTIL Earnings Performance
Company profitability
Upcoming events
No upcoming events
DTIL News
AllArticlesVideos
Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026
Business Wire2 weeks ago
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026
Business Wire1 month ago
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
Business Wire3 months ago
Funds containing DTIL
Fund name | Fund size | $DTIL weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5B | 0.00% |
SPDR Russell 2000 US Small Cap£R2SC | $5B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.